Ex Vivo LPS Stimulation in Healthy and Compromised Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01656915|
Recruitment Status : Completed
First Posted : August 3, 2012
Last Update Posted : June 19, 2013
Ex vivo LPS stimulation of whole blood will be a good alternative challenge to induce an inflammatory response and examine differences in the inflammatory response between healthy and compromised subjects.
The purpose of the current study is to examine the inflammatory response in a younger population (35-45 yrs old) to see whether in this population also differences in the ex vivo LPS induced cytokine response exists between healthy and compromised subjects, as is seen in elderly subjects. Overweight subjects showing a state of disturbed blood glucose control will be included as subjects with compromised health and compared to healthy lean subjects with the same age (shifting from healthy towards unhealthy, not diseased).
Hypothesis Ex vivo LPS stimulation of whole blood will induce a measurable inflammatory cytokine response in a healthy population that is different from a response of the compromised population. The investigators will include subjects aged 35-45 years that differ in health characteristics, especially blood HbA1c, fat% and waist circumference.
|Condition or disease|
|Compromised Health Healthy|
|Study Type :||Observational|
|Actual Enrollment :||36 participants|
|Observational Model:||Case Control|
|Official Title:||Ex Vivo LPS Stimulation in Healthy and Compromised Subjects|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||October 2012|
Healthy male subjects with normal weight
pre-diabetic overweight, male subjects
- Cytokines [ Time Frame: baseline, 4h and 24h incubation with ex vivo LPS ]The levels of interleukines present in healthy and compromised subjects will be determined in a baseline sample.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01656915
|Leiden, Zuid-Holland, Netherlands, 2333 CH|
|Principal Investigator:||Pierre Peeters, PhD||CHDR Leiden|